Rimonabant Acomplia Helps With Weight Loss

Rimonabant acomplia diet weight loss pills are approved now and will be available on sale in all of 25 European Union Countries in July.

The European Commission gave permission for the sale of Rimonabant acomplia prescription weight loss drugs to treat obesity and weight loss with a BMI ( body mass index) of 30 or above as well as for smoking cessation treatments.

“The approval of Rimonabant Acomplia in the European Union is important news for obese and overweight patients with additional cardiometabolic risk factors such as type 2 diabetes or dyslipidaemia who will now have access to an innovative treatment option,” said Sanofi CEO Jean-François Dehecq.

Sanofi said that after the launch of Acomplia (Rimonabant) in the United Kingdom, it will be launched during the second half of 2006 in Denmark, Ireland, Germany, Finland and Norway as well.

Acomplia is different from most other weight loss pills available in the market today in the sense that it does not act on any of the known weight gain factors but uses a totally different approach for weight loss.

Many legitimate Web sites bring customers health products with the benefits of convenience, privacy, and, sometimes, cheaper prices. “But consumers need to be aware that the Internet has also created a marketplace for unapproved medical products, illegal prescribing, and products marketed with fraudulent health claims. So, Being a responsible website, cesaonline.com encourages visitors to go through all the information available about Rimonabant before order rimonabant acomplia online from UK.

Now it is easy to Order Rimonabant a slimming pill online. Now no more exercise, no more weight loss programs and no more machines to reduce your weight and control it. One wonder durg Rimonabant Acomplia can do all for you. Apart from being an effective weight loss and an anti obesity pill, Rimonabant Acomplia has also shown to improve HDL (good cholesterol) and triglyceride levels, showing benefit for diabetes and heart conditions.

So is this now the best way to lose weight?

Not necessarily. As with all diet drugs, there are potential side affects. The group taking the drug were slightly more likely to experience symptoms such as nausea, anxiousness, influenza and depressed mood disorder.Also, most of the patients who were switched to the placebo after one year were seen to regain most of their lost weight by the end of year two, so unless taken every day over a very long period of time, it does not appear to be a permanent solution.(order rimonabant,best way to lose weight)

While the tests have shown positive results, you can comfortably and healthily lose 2lbs per week, more than the majority of the patients involved in the trial, simply by increasing activity and making sensible changes to your diet.So like other medical methods, (order cheap rimonabant,best way to lose weight,and forget about your weight problems) this should be treated as a last resort rather than the first option looked at when starting the fight to lose weight.

We all know pill popping isn’t the answer when it comes to losing weight and keeping if off. But clinical trials with a new anti-obesity drug look promising. The drug, called rimonabant, was developed after scientists noticed that cannabis smokers often had increased appetites and frequently experienced the ‘munchies’.

Clinical trials have found that Rimonabant can help overweight and obese people to lose weight. It was also found that the drug could reduce the risk of cardiovascular heart disease and diabetes, and be of help to people who are trying to stop smoking.

Buy Rimonabant Acomplia - an anti obesity drug for quick weight loss online. Some tests of Rimonabant conducted on humans since last two years have shown significant results on losing weight through rimonabant acomplia pill.

In the most recent trial of rimonabant acomplia, 1507 overweight and obese patients were randomized to receive either placebo or one of two doses of rimonabant (5 mg or 20 mg per day.). Patients taking 20 mg rimonabant had significant weigh loss, and also improvement in lipid profiles, compared to patients on placebo. (Those taking 5 mg of Rimonabant doses also had more weight loss than placebo patients, but the magnitude of weight loss was much less.) In addition, waist measurements significantly improved in rimonabant acomplia patients. There are so many advantages of rimonabant to know.

In the first study of Rimonabant Acomplia, designed to measure the drug’s ability to induce weight loss, 44% of patients who took rimonabant acomplia for 1 year lost more than 10% of their body weight.

Furthermore, Patients treated with rimonabant acomplia tended to have increased HDL cholesterol levels (i.e., the “good” cholesterol) and reduced triglyceride levels.

Studies show that Rimonabant (acomplia) is used to reduce appetite, and thus rimonabant helps the patient who suffers from obesity. Rimonabant also help the patient in metabolism- related health problems.

Order Rimonabant Acomplia online and get a well shaped body today.

How Rimonabant Acomplia works?

• Rimonabant Acomplia is the first of a class of drug, called CB1 blockers, that act on the endocannabinoid system (the EC system), a natural system that modulates the body’s energy balance and nicotine dependence. An over-stimulated EC system is thought to play a role in obesity, and CB1 blockers are supposed to reduce this overstimulation for food intake.

• There are nerve receptors that exist in the brain and fat cells. These receptors tell the body to overeat. Rimonabant Acomplia blocks the signals these receptors give out - it stops them from telling us to overeat. Overeaters have very active receptors of this kind. By blocking the signals, the overeater does not have the same urge to eat. There is no other drug like Rimonabant Acomplia which helps you stop overeating.

Order Rimonabant Acomplia online from here and see the wonder of Rimonabant over obesity and overweight today !

Acomplia (Rimonabant) - Investigational Agent for the Management of Obesity

 Buy Acomplia  online for TREATMENT OF OBESITY

Under development by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity.

“Acomplia is a selective CB1 endocannabinoid receptor antagonist.”

It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a novel therapeutic approach to appetite control and weight reduction.

Obesity is now the most common nutritional disorder in western industrialised countries and arises from the accumulation of excess fat in the body from over consumption of fatty foods. 

Data from the World Health Organisation’s MONICA project show that in some parts of Europe over 70% of men aged 55-64 years are clinically obese or overweight (BMI >25) and almost 70% of women in this age group. One in five of all Americans is obese and one in three overweight. Furthermore, increasing rates of childhood obesity are likely to exacerbate the trend towards increasing obesity in adulthood.

“The central cannabinoid (CB1) receptors are believed to play a role in controlling food consumption.”

There is a strong association between obesity and increased risk of cardiovascular disease and diabetes and possibly certain cancers, such as breast and colorectal cancer.

The dramatic rise in the incidence of type 2 diabetes is due largely to the increased prevalence of obesity. Increases in body weight lead to changes in blood lipid and cholesterol levels, predisposing to increased risk of atherosclerosis.

THERAPEUTIC APPROACHES TO TREATMENT OF OBESITY

Not surprisingly, the growing prevalence of obesity has stimulated the search for drugs to treat this condition. Various therapeutic strategies have been explored, including:

• Serotonin and noradrenaline reuptake inhibitors (anorectic agents)
• Lipase inhibitors
• ß 3-adrenoreceptor agonists
• Leptin agonists
• Melanocortin-3 agonists

Sanofi-Aventis’ approach is completely different to the above. It developed from the knowledge that cannabis smokers often experience extreme hunger pangs, which cannabis smokers refer to as “the munchies”. Sanofi-Aventis worked on the premise that if cannabinoids stimulate appetite, blocking cannabinoid receptors in the brain might reduce appetite.

The central cannabinoid (CB1) receptors are believed to play a role in controlling food consumption and the phenomena of dependence / habituation. To develop suitable drugs against this target, the human cannabinoid receptor was first cloned and then expressed in cells.

Compounds with potential inhibitory activity against this receptor were then screened for inhibitory activity. Rimonabant emerged from this screening process as a potent CB1 receptor antagonist. Preclinical animal studies subsequently showed that it could reduce consumption of fats and sugars, which contribute to weight gain.

PHASE III DATA HIGHLIGHT EFFICACY AND SAFETY

The promising preclinical findings with Acomplia (rimonabant) have been confirmed in a series of clinical studies, including pivotal phase III trials involving over 6,000 obese subjects that were carried out in both the US and Europe.

Two-year data from the phase III multicentre Rimonabant In Obesity (RIO) trials, which compared rimonabant at doses of 5mg and 20mg with placebo with respect to weight reduction and prevention of weight gain, showed that the positive results seen after a year’s treatment were sustained over the full two-year trial period.

“There is a strong association between obesity and increased risk of cardiovascular disease, diabetes and possibly certain cancers.”

Consistent with the one-year data, the results showed that overweight and obese patients taking rimonabant 20mg/d achieved significant reductions in body weight, waist circumference (an indicator of abdominal obesity) and improved lipid and glycaemic profiles compared with placebo recipients. Rimonabant also had a significant impact on metabolic CVD risk factors, greater than that expected by weight loss alone.

Efficacy and safety in long-term use is important feature of any antiobesity drug. Some potential antiobesity medications have proved effective in the first six months of treatment only to lose effectiveness as subjects develop resistance to treatment.

Data from the RIO trials suggest rimonabant is effective for maintaining weight loss for periods of at least two years. Long-term safety is also a major concern. In the US, the FDA generally requires two years of safety data before approving antiobesity drugs.

Results from the phase III RIO trial programme suggest rimonabant is well tolerated in long-term use. Among patients who were randomly assigned to continue their first-year treatment for a second year, 6.7%, 8.3% and 6.0% discontinued from the placebo, rimonabant 5mg and 20mg groups respectively.

The ongoing phase IIIb trial programme for rimonabant includes studies in patients with diabetes (SERENADE), dyslipidaemia (ADAGIO) and cardiovascular disease (STRADIVARIUS, AUDITOR, CRESCENDO).

“There is a strong association between obesity and increased risk of cardiovascular disease, diabetes and possibly certain cancers” so Buy Acomplia for TREATMENT OF OBESITY now !

What is Acomplia ?

Accomplia is such a wonder drug that preliminary trials have shown that 33% of people who were put on Acomplia lost 10% of weight and could maintain that for two years. Acomplia also helped to quit smoking and in promoting healthy lipid levels thus protecting the cardiovascular system

A weight loss of 5 to 10% can help in reducing risks of obesity-related diseases and delay/prevent type 2 diabetes in persons with high risk. Obesity is nowadays a very common nutritional disorder owing to today’s stress filled lives in western countries. A person with Body mass index is said to be obese.

As well as keeping you lean, the drug also acts as antismoking drug. This will be of great interest for many smokers as they say they will put on loads of weight if they do (usually young female smokers worry about this the most).

A single pill has been found to stop both food and cigarette cravings enough to help people quit smoking and lose weight, and could also help curb other unhealthy urges. Named Acomplia the drug in one study helped people who were overweight drop an average of 20 pounds and in another doubled the chances that smokers would quit. Acomplia is made by French firm Sanofi-Synthelabo and the company says it could be available as early as 2006. Acomplia contains the active ingredient Rimonabant.

How Acomplia works?

Human’s have nerve receptors in the brain and fat cells which prompt us to overeat or indulge in smoking. Acomplia blocks the signals these receptors give out to the brain thus decreasing the wish to eat more or do more smoking. Overeater’s and addicted smokers have very active receptors of these type which are blocked from informing the brain to carry out a particular operation.

Rimonabant (which will be brought to market as Acomplia) works by blocking the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System), believed to play a critical role in the regulation of food intake and energy expenditure.

Researchers wondered whether a drug that halted this action might curb appetite, and in 2001, the first animal study was conducted at the National Institute of Alcohol Abuse and Alcoholism in Bethesda, Md.

In the study, genetically altered mice that lacked cannabinoid receptors ate less than their litter mates, even after 18 hours of fasting. When the normal mice were given rimonabant, which blocked their CB1 receptors, the mice reduced their food intake.In 2002, Sanofi-Synthelabo began human testing.

Acomplia works by selectively targeting and blocking the CB1 receptors, helping normalize the over-activation of the EC system and making hunger or cigarette cravings more manageable.

This blocking of signals that control cravings appears to result in weight loss, improvement of cardiovascular/ metabolic risk factors in overweight/obese patients and appears to reduce tobacco dependence without post cessation weight gain in people who smoke.

Advantages and side effects :

Advantages of Acomplia  include weight loss, easiness in quitting smoking or reduction in smoking and lowering of cardiovascular risk.
Acomplia was said to be well tolerated in early tests. The only relatively common side effects were mild GI side effects and dizziness, and these were said to be transient.

Acomplia has certain minor side effects. Nausea, headache, irritability and dizziness are certain side effects you should expect when you order Acomplia online. However, these side effects are transient in nature and will go away once your body adjusts to the medication.
Order acomplia online for weight loss and anti smoking drug.
Buy Acomplia online at http://www.rimonabant-acomplia.co.uk – play safe!!

One of the hot new diet drug in the news is the French drug called “Accomplia Rimonabant.” It was created to help people quit smoking and lose fat by blocking circuitry in the brain that gives the body cravings. The diet drug, rimonabant accomplia, which could be available in a year or two, is an appetite suppressant, but works by an entirely new approach by blocking the same primeval circuitry in the brain that gives pot-smokers the munchies. The French firm Sanofi-Synthelabo plans to seek U.S. approval to sell it under the brand “Accomplia” after more studies are finished next year. A study found that the drug helped people drop 20 pounds in a year, while the other concluded it increased smokers’ success at quitting, at least in the short-term. The drug will be marketed both for dieting and smoking cessation.

Doctors say the drug is noteworthy because it takes a different approach to helping people overcome their cravings for food and tobacco. It is the first of a class of medicines that blocks the so-called endocannabinoid system in the central nervous system.

Marijuana makes people hungry by stimulating this circuitry. The same biology serves crucial everyday purposes by helping the brain regulate hunger, including alcohol craving. Overeating and smoking can overstimulate this system, which in turn causes people to eat and smoke more. By temporarily blocking the body’s ability to receive these signals, experts believe they can return the system to normal.

In the larger of the two studies, Dr. Jean-Pierre Despres of Laval University in Quebec City used 1,036 volunteers, all with stomachs that put them at high risk for heart problems. They were urged to cut 600 calories/day and given either accomplia or placebos.

After a year, those who got the higher of two doses of accomplia had lost an average of 20 pounds and trimmed three inches from their waists. Nearly half of them took off 10 percent of their body weight. By comparison, those on placebos lost just five pounds. Those receiving accomplia improved in other ways, as well: their levels of good cholesterol rose 23 percent, while their triglycerides fell 15 percent.

Commentary: This seems to be another expensive diet drug with unknown long-term side-effects. In their own study, they showed a 20 pound weight loss over a year versus 5 pounds on the placebo. Only fifteen pounds difference? This is hardly the miracle diet pill we’ve all been looking for. Realize those who lose weight and keep it off almost always follow the same strategy: balanced nutrition with portion control, daily exercise and especially important, they find a long-term motivation to change their lifestyle.